HomeNewsBusinessMarkets‘Next 1,000 points rally on Nifty will be driven by IT, consumption, pharma plays’

‘Next 1,000 points rally on Nifty will be driven by IT, consumption, pharma plays’

Vinod Nair, Head of Research at Geojit Financial Services, said the focus will continue on strong market leaders with stable and sustainable businesses

July 25, 2018 / 16:45 IST
Story continues below Advertisement

Kshitij Anand Moneycontrol News

Vinod Nair, Head of Research at Geojit Financial Services, said the focus will continue on strong market leaders with stable and sustainable businesses. “Defensive sectors like IT, FMCG, pharma and consumption-oriented companies appear attractive.”

Edited excerpts

Story continues below Advertisement

Q) What is the way forward for markets, some consolidation or a one- way rally? A) We are still within a long term bull rally. This consolidation phase can continue till domestic earnings growth returns, political fears settle, global bond yield normalise and risk-off trend reverses.

Q) Market is at a record high but most investors are not happy because the value of their portfolio are not reflecting the same sentiment. What should investors do now: wait patiently or churn your portfolio? A) We have been asking retail investors to shift their equity exposure from mid- and smallcaps to largecaps. Some midcaps have become attractive after this correction and can be considered for the long-term.

Q) Which stocks will drive next 1,000 points rally on the index? A) We feel the focus will continue on strong leaders with stable and sustainable businesses in defensives: IT, FMCG, pharma and consumption-oriented companies like autos, electronics and aviation.

Q) Any sectors which could be a dark horse in 2018? A) Given the muted pharma outlook, the earnings forecast is subpar. The low valuation may not have been completely factored in, providing volatility in the near term, but this could lead to long term investment opportunities for those using the systematic investment route.

A large portion of the loss in revenue is accruing from regulated markets, especially the US. This is largely factored in and earnings growth will take some time to come back.

The Trump administration had come out with a blueprint of their pharma policy. As of now, it doesn’t look very negative for Indian companies, though there is a lack of clarity on the implementation side. Increasing drug approvals from the US Food and Drug Administration is keeping sentiment positive.